Evidence map›Paper›PMID 26331372›Full record

ArticleThe Journal of pathology2016

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Michael C Haffner, Christopher Weier, Meng Meng Xu, Ajay Vaghasia, Bora Gürel, Berrak Gümüşkaya, David M Esopi, Helen Fedor, Hsueh-Li Tan, Ibrahim Kulac and 6 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Guideline
  2. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Michael C HaffnerSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Christopher WeierSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Meng Meng XuDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA.
Ajay VaghasiaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Bora GürelDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Berrak GümüşkayaDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
David M EsopiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Helen FedorDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Hsueh-Li TanDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Ibrahim KulacDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Jessica HicksDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
William B IsaacsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Tamara L LotanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
William G NelsonSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Srinivasan YegnasubramanianSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Angelo M De MarzoSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · USDuke University · USJohns Hopkins Medicine · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI ISAACS, JOHN TOD · 1992 to 2020
$43.9M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
GSTPI PROMOTOR HYPERMETHYLATION IN HUMAN PROSTATE CANCERR01CA070196 · NCI · JOHNS HOPKINS UNIVERSITY · PI NELSON, WILLIAM GEORGE · 1996 to 2012
$3.9M
Role of TOP2B in generating complex genomic rearrangements in human cancerR01CA183965 · NCI · JOHNS HOPKINS UNIVERSITY · PI WHEELAN, SARAH J, YEGNASUBRAMANIAN, SRINIVASAN · 2014 to 2018
$1.7M
NCI NIH HHS P30 CA006973NCI NIH HHS P30CA006973NCI NIH HHS P50 CA058236NCI NIH HHS P50CA058236NCI NIH HHS P50CA58236NCI NIH HHS R01 CA070196NCI NIH HHS R01CA070196NCI NIH HHS R01 CA183965NCI NIH HHS R01CA183965NIGMS NIH HHS T32 GM008752
6 · The paper itself

Abstract

Prostate cancer often manifests as morphologically distinct tumour foci and is frequently found adjacent to presumed precursor lesions such as high-grade prostatic intraepithelial neoplasia (HGPIN). While there is some evidence to suggest that these lesions can be related and exist on a pathological and morphological continuum, the precise clonal and temporal relationships between precursor lesions and invasive cancers within individual tumours remain undefined. Here, we used molecular genetic, cytogenetic, and histological analyses to delineate clonal, temporal, and spatial relationships between HGPIN and cancer lesions with distinct morphological and molecular features. First, while confirming the previous finding that a substantial fraction of HGPIN lesions associated with ERG-positive cancers share rearrangements and overexpression of ERG, we found that a significant subset of such HGPIN glands exhibit only partial positivity for ERG. This suggests that such ERG-positive HGPIN cells either rapidly invade to form adenocarcinoma or represent cancer cells that have partially invaded the ductal and acinar space in a retrograde manner. To clarify these possibilities, we used ERG expression status and TMPRSS2-ERG genomic breakpoints as markers of clonality, and PTEN deletion status to track temporal evolution of clonally related lesions. We confirmed that morphologically distinct HGPIN and nearby invasive cancer lesions are clonally related. Further, we found that a significant fraction of ERG-positive, PTEN-negative HGPIN and intraductal carcinoma (IDC-P) lesions are most likely clonally derived from adjacent PTEN-negative adenocarcinomas, indicating that such PTEN-negative HGPIN and IDC-P lesions arise from, rather than give rise to, the nearby invasive adenocarcinoma. These data suggest that invasive adenocarcinoma can morphologically mimic HGPIN through retrograde colonization of benign glands with cancer cells. Similar clonal relationships were also seen for intraductal carcinoma adjacent to invasive adenocarcinoma. These findings represent a potentially undervalued indicator of pre-existing invasive prostate cancer and have significant implications for prostate cancer diagnosis and risk stratification.

Indexed as

AdenocarcinomaCarcinoma, Intraductal, NoninfiltratingCell Line, TumorDiagnosis, DifferentialHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleNeoplasm InvasivenessOncogene Proteins, FusionProstatic Intraepithelial NeoplasiaProstatic NeoplasmsPTEN PhosphohydrolaseTrans-ActivatorsTranscriptional Regulator ERGERG protein, humanOncogene Proteins, FusionPTEN PhosphohydrolasePTEN protein, humanTMPRSS2-ERG fusion protein, humanTrans-ActivatorsTranscriptional Regulator ERGclonalityductal spreadingERGprostate cancerprostatic intraepithelial neoplasiaPTEN

Identifiers

PMID26331372
PMCPMC4715537
OpenAlexW1901104231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.